Media stories about Entellus Medical (NASDAQ:ENTL) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Entellus Medical earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the medical technology company an impact score of 44.9481487290387 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Several research analysts have weighed in on the company. ValuEngine upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. William Blair downgraded Entellus Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, December 8th. Piper Jaffray Companies restated a “buy” rating and issued a $21.00 price target on shares of Entellus Medical in a research note on Tuesday, August 22nd. BidaskClub upgraded Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $17.00 target price on shares of Entellus Medical in a research report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. Entellus Medical presently has an average rating of “Hold” and an average price target of $20.40.

Entellus Medical (NASDAQ ENTL) opened at $24.28 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.71 and a current ratio of 1.92. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $24.88.

In other news, VP Kevin L. Mensink sold 2,500 shares of the stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $19.00, for a total transaction of $47,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian E. Farley sold 101,319 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $23.85, for a total value of $2,416,458.15. The disclosure for this sale can be found here. Insiders have sold a total of 168,469 shares of company stock valued at $3,718,611 over the last quarter. Corporate insiders own 7.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with's FREE daily email newsletter.